Department of Medical Microbiology (Schering AG)

Error creating thumbnail:

Bild-Cecil − Foto-Exkursion Berlin 2008 − Bayer Schering Pharma

Department of Medical Microbiology (Schering AG) was a pivotal research division within Schering AG, a German pharmaceutical company. This department played a crucial role in the development of microbial-based medicines and contributed significantly to the field of medical microbiology. Schering AG, established in 1851, was renowned for its contributions to pharmaceuticals, and the Department of Medical Microbiology was at the forefront of exploring the therapeutic potential of microorganisms.

History

The Department of Medical Microbiology was established in the early 20th century, a time when the medical community was beginning to recognize the importance of microorganisms in disease and health. Schering AG, already a leader in the pharmaceutical industry, invested in this department to spearhead research in antibiotics, vaccines, and other microbial products. The department's work was instrumental in the discovery and development of several key treatments that have had a lasting impact on public health.

Research and Development

The Department of Medical Microbiology at Schering AG focused on several key areas of research:

• Antibiotic Discovery: The department was involved in the screening of soil and other natural sources for organisms that could produce substances with antibacterial properties. This work contributed to the broader field of antibiotic discovery, which was crucial in the era before widespread antibiotic resistance.

• Vaccine Development: Research into vaccines for various infectious diseases was another cornerstone of the department. This included both the development of new vaccines and the improvement of existing ones.

• Microbial Physiology: Understanding the life processes of microorganisms was essential for manipulating them for medical purposes. The department conducted research into the genetics, biochemistry, and physiology of bacteria, fungi, and viruses.

• Clinical Microbiology: The department also worked closely with clinical partners to understand the microbial causes of diseases and to develop diagnostic tests and treatments.

Impact

The contributions of the Department of Medical Microbiology at Schering AG have had a significant impact on the field of medical microbiology and public health. The development of new antibiotics and vaccines has saved countless lives and improved the quality of life for many more. Additionally, the department's research has advanced the scientific community's understanding of microbial physiology and genetics, laying the groundwork for future innovations.

Legacy

Schering AG was acquired by Bayer AG in 2006, and the legacy of the Department of Medical Microbiology continues under the Bayer umbrella. The research and discoveries made by the department remain foundational to ongoing efforts in combating infectious diseases and in the development of new microbial-based therapies.